CVS Health (1CVS) AI Stock Analysis

CVS Health

(Milan:1CVS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Cash generation and deleveragingStrong and improving cash generation gives CVS greater capacity to fund operations, reduce debt, and invest in healthcare capabilities. The concurrent deleveraging trend improves financial flexibility and provides a more durable foundation for managing reimbursement or utilization pressure.

Negative Factors

Compressed profitabilityVery thin and reduced margins leave CVS with limited earnings cushion when medical costs, reimbursement, or operating expenses increase. Although revenue remains large, weaker profitability and depressed returns indicate that scale is not currently translating into consistently strong economic efficiency.

CVS Health (1CVS) vs. iShares MSCI Italy ETF (EWI)

Market Cap: EUR 113.20B
Dividend Yield: 3.00%
Average Volume (3M): 53
Price to Earnings (P/E): 23.1
Beta (1Y): 0.09
Revenue Growth: 0.14%
EPS Growth: -1.47%
Country: Italy
Employees: 259,500
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Plans

CVS Health Business Overview & Revenue Model

Company Description

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Hea...

CVS Health Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-12.28%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call conveyed strong operational and financial momentum across segments with material upside: double-digit growth in operating income, raised EPS guidance, improved cash flow outlook, specialty leadership, and early tangible AI-driven efficiencies. Offsetting these positives are notable industry-specific headwinds—most prominently near-term 340B pressures, anticipated Caremark membership declines in 2027, ongoing reimbursement and regulatory pressures, and some timing-related pull-forwards. Management emphasized disciplined execution, balance sheet improvement and a multi-year growth outlook (mid-teens EPS CAGR through 2028), while acknowledging and preparing for specific near-term headwinds.

Positive Updates

Strong top-line performance

Total revenue exceeded $106 billion in Q2 2026, an increase of over 7% year-over-year, with full year 2026 total revenues now expected to be at least $414 billion.

Negative Updates

340B program pressure

Management disclosed pressure in the 340B business during the quarter driven by a dynamic program environment and manufacturer restrictions; they expect 340B to be a headwind into 2027 (no specific dollar amount provided).

Company Guidance

CVS raised its full‑year 2026 outlook, increasing adjusted EPS guidance to $7.90–$8.10 (up $0.60, ~+8%), raising expected cash flow from operations to at least $11.5B (up ~$2B), and targeting total revenues of at least $414B; enterprise adjusted operating income is now expected to be $16.58–$16.92B, Health Care Benefits adjusted operating income $5.03–$5.37B (up >$1B), with an expected MBR of 89.75% ±25 bps, Pharmacy & Consumer Wellness adjusted operating income at least $6.4B (up $220M) and Health Services outlook reiterated; management noted Q2 results of $5.2B adjusted operating income and $2.58 adjusted EPS, YTD cash flow from operations of ~$10.6B, parent cash of ~$2.7B and leverage of ~3.5x, said no share repurchases are assumed in the current outlook, expects second‑half EPS weighted to Q3, anticipates the Q1–Q4 MBR increase in Health Care Benefits to be slightly above 950 bps (adjusted for prior‑year development), reiterated a mid‑teens adjusted EPS CAGR for 2025–2028, and provided preliminary 2027 context implying a reasonable floor of at least $8.44 (≈13% growth off a $7.46 adjusted baseline, excluding prior‑year development and individual‑exchange items).

CVS Health Risk Analysis

CVS Health disclosed 40 risk factors in its most recent earnings report. CVS Health reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

CVS Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IT:1CVS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CI	72Outperform	$78.80B	12.17	15.24%	2.10%	8.15%	31.47%
ELV	69Neutral	$90.76B	17.61	11.59%	1.66%	3.60%	-4.06%
CNC	64Neutral	$33.89B	22.48	6.78%	―	9.71%	―
UNH	62Neutral	$365.29B	22.85	16.10%	2.26%	3.33%	―
HUM	60Neutral	$49.77B	38.54	6.91%	0.86%	18.33%	-18.53%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

IT:1CVS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IT:1CVS	CVS Health Corp	79.00	12.83	19.40%
CNC	Centene	66.53	30.42	84.24%
CI	Cigna	295.19	36.40	14.06%
HUM	Humana	410.41	132.17	47.50%
UNH	Unitedhealth Group Inc.	400.44	78.19	24.26%
ELV	Elevance Health, Inc.	413.60	103.15	33.23%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CVS Health AI Stock Analysis